Lab result ingestion
Support CBC, CMP, lipid, HbA1c, ApoB, Lp(a), hs-CRP, thyroid, vitamin, renal, liver, hormone, and therapeutic monitoring data.
Diagnostics Intelligence
Turn IVD and lab data into clinician-reviewed insight.
Normalize bloodwork, biomarker panels, and diagnostic reports into longitudinal patient profiles that support safer therapy review and personalized monitoring.
Third-party lab data normalization for downstream algorithm modules. Designed for FDA clearance pathway as Software as a Medical Device; no clearance has been granted. Concept-phase prototype.
| Biomarker | Value | Trend | Reference | Status | Collection | Source | Provenance |
|---|---|---|---|---|---|---|---|
HbA1c LOINC 4548-4 | 6.1 % | 5.4→6.1 | 4 to 5.6 % | high | 2026-04-20 | Third-party CLIA/CAP lab | lab report |
ApoB LOINC 1884-6 | 115 mg/dL | 102→115 | - to 100 mg/dL | high | 2026-04-20 | Third-party CLIA/CAP lab | lab report |
Lp(a) LOINC 43583-4 | 80 nmol/L | 78→80 | - to 75 nmol/L | high | 2026-04-20 | Third-party CLIA/CAP lab | lab report |
eGFR LOINC 98979-8 | 72 mL/min/1.73m2 | 81→72 | 90 to - mL/min/1.73m2 | low | 2026-04-20 | Third-party CLIA/CAP lab | lab report |
ALT LOINC 1742-6 | 42 U/L | 28→42 | 7 to 35 U/L | high | 2026-04-20 | Third-party CLIA/CAP lab | lab report |
IVD/lab workflow
From diagnostic reports to traceable decision support.
Biomarker trend analysis
Display longitudinal placeholders so clinicians can review values in context instead of isolated snapshots.
Diagnostic report normalization
Model panels as FHIR-ready DiagnosticReports and individual biomarkers as Observation-like records.
Medication safety context
Connect renal, hepatic, metabolic, and cardiovascular markers to clinician-reviewed medication safety flags.
Longitudinal monitoring
Combine lab values with wearable trends, medication timelines, and patient-reported tolerability.
Clinician-reviewed recommendations
Every insight displays trigger data, evidence placeholders, and careful review language.
FHIR-ready design
DiagnosticReport for panels. Observation for values.
The data model keeps IVD results integration-ready while preserving source, status, and collection context.
HbA1c, ApoB, Lp(a), eGFR, ALT, and hs-CRP observations
Third-party CLIA/CAP lab source placeholders
Reference ranges, status flags, LOINC placeholders, and collection dates
Rules-based insights with evidence-linked clinician review language
Early access
Bring Diagnostics Intelligence into personalized medicine.
See how pharmacogenomics, third-party lab results, medications, and wearable trends come together in a clinician-reviewed workflow.